Callan Family Office LLC Has $3.27 Million Stock Position in AstraZeneca PLC $AZN

Callan Family Office LLC lessened its position in AstraZeneca PLC (NASDAQ:AZN) by 23.5% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 42,680 shares of the company’s stock after selling 13,134 shares during the quarter. Callan Family Office LLC’s holdings in AstraZeneca were worth $3,274,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Brighton Jones LLC lifted its holdings in shares of AstraZeneca by 93.2% in the fourth quarter. Brighton Jones LLC now owns 5,782 shares of the company’s stock valued at $379,000 after purchasing an additional 2,789 shares in the last quarter. AQR Capital Management LLC raised its position in AstraZeneca by 45.3% during the first quarter. AQR Capital Management LLC now owns 37,501 shares of the company’s stock valued at $2,756,000 after buying an additional 11,690 shares during the period. Simplicity Wealth LLC lifted its stake in AstraZeneca by 4.5% in the 2nd quarter. Simplicity Wealth LLC now owns 7,862 shares of the company’s stock worth $549,000 after acquiring an additional 335 shares in the last quarter. Grimes & Company Inc. boosted its position in AstraZeneca by 3.0% during the 2nd quarter. Grimes & Company Inc. now owns 5,290 shares of the company’s stock worth $370,000 after acquiring an additional 155 shares during the period. Finally, DAVENPORT & Co LLC grew its stake in AstraZeneca by 5.3% during the 2nd quarter. DAVENPORT & Co LLC now owns 17,817 shares of the company’s stock valued at $1,245,000 after acquiring an additional 904 shares in the last quarter. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

AstraZeneca Trading Down 2.0%

Shares of NASDAQ:AZN opened at $184.64 on Wednesday. The company has a current ratio of 0.88, a quick ratio of 0.69 and a debt-to-equity ratio of 0.54. The stock has a market capitalization of $572.73 billion, a PE ratio of 61.34, a P/E/G ratio of 1.59 and a beta of 0.34. AstraZeneca PLC has a 1 year low of $61.24 and a 1 year high of $192.79. The firm has a fifty day moving average price of $96.05 and a 200 day moving average price of $86.13.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings results on Thursday, November 6th. The company reported $1.19 earnings per share for the quarter, topping analysts’ consensus estimates of $1.14 by $0.05. The company had revenue of $15.19 billion during the quarter, compared to analysts’ expectations of $14.75 billion. AstraZeneca had a return on equity of 32.89% and a net margin of 16.17%.The business’s quarterly revenue was up 12.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.08 earnings per share. Analysts expect that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

More AstraZeneca News

Here are the key news stories impacting AstraZeneca this week:

• Positive Sentiment: Deal strengthens obesity pipeline — AstraZeneca struck an eight-program deal with China’s CSPC for a once‑monthly injectable weight-management program, which could accelerate its obesity franchise and long-term growth prospects. AZN Obesity Pipeline to Get a Boost From Deal With China’s CSPC
• Positive Sentiment: High-profile endorsement — CNBC’s Jim Cramer publicly said he likes AstraZeneca, which can provide short-term sentiment support among retail investors. Jim Cramer says “I like AstraZeneca very much”
• Positive Sentiment: NYSE listing / harmonized U.S. trading — AstraZeneca began direct trading on the NYSE (ending the ADS program), simplifying U.S. ownership and potentially boosting liquidity and investor access. AstraZeneca begins trading directly on the NYSE
• Neutral Sentiment: Earnings cadence — The company is expected to report results soon; investors will focus on revenue growth and guidance for clarity on near-term momentum. AstraZeneca (AZN) Expected to Announce Earnings on Tuesday
• Neutral Sentiment: Short‑interest data appears unreliable — recent reports show zero shares/NaN changes and a 0.0 days-to-cover metric, indicating a data glitch rather than actionable market pressure.
• Neutral Sentiment: Market commentary explaining the pullback — Coverage notes AstraZeneca fell more than the broader market today, providing context for the move. Why Astrazeneca (AZN) Dipped More Than Broader Market Today
• Negative Sentiment: FDA issued a complete response letter (CRL) on Saphnelo’s BLA — the CRL is a material regulatory setback that delays potential U.S. approval and near-term revenue from this asset. FDA issues CRL on AstraZeneca’s Saphnelo BLA
• Negative Sentiment: Initial U.S. application for a lupus injection was turned down — AstraZeneca is working with the FDA and plans an updated submission, but this prolongs the approval timeline and creates near-term uncertainty for the program. AstraZeneca’s Initial Application for Lupus Injection Turned Down by FDA

Analyst Ratings Changes

Several research firms recently commented on AZN. Guggenheim restated a “buy” rating on shares of AstraZeneca in a report on Wednesday, December 3rd. Weiss Ratings reissued a “buy (b)” rating on shares of AstraZeneca in a research note on Wednesday, January 21st. Citigroup started coverage on shares of AstraZeneca in a research note on Tuesday, January 27th. They issued a “buy” rating on the stock. TD Cowen reiterated a “buy” rating on shares of AstraZeneca in a report on Tuesday, December 9th. Finally, Morgan Stanley restated an “overweight” rating and issued a $103.00 target price on shares of AstraZeneca in a research note on Wednesday, December 3rd. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $95.75.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.